TRVI Trevi Therapeutics Inc

USD 3.06 -0.02 ( -0.65)%
Icon

Trevi Therapeutics Inc (TRVI) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 3.06

-0.02 (-0.65)%

USD 0.23B

0.29M

USD 7.22(+139.94%)

N/A

Icon

TRVI

Trevi Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 3.06
-0.02 ( -0.65)%
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.23B

N/A

USD 3.06

Trevi Therapeutics Inc (TRVI) Stock Forecast

Show ratings and price targets of :
USD 7.22
(+139.94%)

Based on the Trevi Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for Trevi Therapeutics Inc is USD 7.22 over the next 12 months. Trevi Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Trevi Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Trevi Therapeutics Inc’s stock price was USD 3.06. Trevi Therapeutics Inc’s stock price has changed by -4.67% over the past week, -8.38% over the past month and +73.86% over the last year.

No recent analyst target price found for Trevi Therapeutics Inc
No recent average analyst rating found for Trevi Therapeutics Inc

Company Overview Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central ...Read More

195 Church Street, New Haven, CT, United States, 06510

26

December

USD

USA

Adjusted Closing Price for Trevi Therapeutics Inc (TRVI)

Loading...

Unadjusted Closing Price for Trevi Therapeutics Inc (TRVI)

Loading...

Share Trading Volume for Trevi Therapeutics Inc Shares

Loading...

Compare Performance of Trevi Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for TRVI

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Trevi Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.72 (+1.00%) USD121.32B 32.57 250.40

Frequently Asked Questions About Trevi Therapeutics Inc (TRVI) Stock

Based on ratings from 7 analysts Trevi Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 9 buy, sell and hold ratings.

Unfortunately we do not have enough data on TRVI's stock to indicate if its a good dividend stock.

Based on targets from 7 analysts, the average taret price for TRVI is USD 7.22 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on TRVI's stock to indicate if its overvalued.

The last closing price of TRVI's stock was USD 3.06.

The most recent market capitalization for TRVI is USD 0.23B.

Based on targets from 7 analysts, the average taret price for TRVI is projected at USD 7.22 over the next 12 months. This means that TRVI's stock price may go up by +139.94% over the next 12 months.

We can't find any ETFs which contains Trevi Therapeutics Inc's stock.

As per our most recent records Trevi Therapeutics Inc has 26 Employees.

Trevi Therapeutics Inc's registered address is 195 Church Street, New Haven, CT, United States, 06510. You can get more information about it from Trevi Therapeutics Inc's website at https://www.trevitherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Frequently Asked Questions About Trevi Therapeutics Inc (TRVI) Stock

Based on ratings from 7 analysts Trevi Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 9 buy, sell and hold ratings.

Unfortunately we do not have enough data on TRVI's stock to indicate if its a good dividend stock.

Based on targets from 7 analysts, the average taret price for TRVI is USD 7.22 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on TRVI's stock to indicate if its overvalued.

The last closing price of TRVI's stock was USD 3.06.

The most recent market capitalization for TRVI is USD 0.23B.

Based on targets from 7 analysts, the average taret price for TRVI is projected at USD 7.22 over the next 12 months. This means that TRVI's stock price may go up by +139.94% over the next 12 months.

We can't find any ETFs which contains Trevi Therapeutics Inc's stock.

As per our most recent records Trevi Therapeutics Inc has 26 Employees.

Trevi Therapeutics Inc's registered address is 195 Church Street, New Haven, CT, United States, 06510. You can get more information about it from Trevi Therapeutics Inc's website at https://www.trevitherapeutics.com.
Loading...